233 related articles for article (PubMed ID: 36612311)
1. Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer.
Puisset F; Mseddi M; Mourey L; Pouessel D; Blanchet B; Chatelut E; Chevreau C
Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612311
[TBL] [Abstract][Full Text] [Related]
2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
3. Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring.
Noda S; Morita SY; Terada T
Biol Pharm Bull; 2022; 45(7):814-823. PubMed ID: 35786588
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring and tyrosine kinase inhibitors.
Herviou P; Thivat E; Richard D; Roche L; Dohou J; Pouget M; Eschalier A; Durando X; Authier N
Oncol Lett; 2016 Aug; 12(2):1223-1232. PubMed ID: 27446421
[TBL] [Abstract][Full Text] [Related]
5. Adaptive control methods for the dose individualisation of anticancer agents.
Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
[TBL] [Abstract][Full Text] [Related]
6. Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study.
Escudero-Ortiz V; Domínguez-Leñero V; Catalán-Latorre A; Rebollo-Liceaga J; Sureda M
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745789
[TBL] [Abstract][Full Text] [Related]
7. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data.
Bandiera C; Cardoso E; Locatelli I; Digklia A; Zaman K; Diciolla A; Cristina V; Stravodimou A; Veronica AL; Dolcan A; Sarivalasis A; Liapi A; Bouchaab H; Orcurto A; Dotta-Celio J; Peters S; Decosterd L; Widmer N; Wagner D; Csajka C; Schneider MP
JMIR Res Protoc; 2021 Jun; 10(6):e30090. PubMed ID: 34185020
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
[TBL] [Abstract][Full Text] [Related]
10. Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.
Cardoso E; Csajka C; Schneider MP; Widmer N
Clin Pharmacokinet; 2018 Jan; 57(1):1-6. PubMed ID: 28634655
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd LA; Widmer N; Zaman K; Cardoso E; Buclin T; Csajka C
Biomark Med; 2015; 9(9):887-93. PubMed ID: 26333311
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and therapeutic drug monitoring of anticancer protein/kinase inhibitors.
Bouchet S; Molimard M
Therapie; 2022; 77(2):157-170. PubMed ID: 35101282
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of pazopanib administered in combination with bevacizumab.
Imbs DC; Négrier S; Cassier P; Hollebecque A; Varga A; Blanc E; Lafont T; Escudier B; Soria JC; Pérol D; Chatelut E
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1189-96. PubMed ID: 24705975
[TBL] [Abstract][Full Text] [Related]
14. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Yu H; Steeghs N; Nijenhuis CM; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2014 Apr; 53(4):305-25. PubMed ID: 24566736
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC.
Ozbey AC; Combarel D; Poinsignon V; Lovera C; Saada E; Mir O; Paci A
Pharmaceuticals (Basel); 2021 Sep; 14(9):. PubMed ID: 34577627
[TBL] [Abstract][Full Text] [Related]
16. Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids.
Bénit CP; Vecht CJ
Neurooncol Pract; 2016 Dec; 3(4):245-260. PubMed ID: 31385988
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.
Hulin A; Stocco J; Bouattour M
Clin Pharmacokinet; 2019 Aug; 58(8):983-1014. PubMed ID: 31093928
[TBL] [Abstract][Full Text] [Related]
18. Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors.
Centanni M; Friberg LE
Front Pharmacol; 2020; 11():316. PubMed ID: 32226388
[TBL] [Abstract][Full Text] [Related]
19. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
20. [Individualization of drug dosage by therapeutic monitoring in plasma and the application of pharmacokinetic principles].
Klotz U
J Clin Chem Clin Biochem; 1983 Nov; 21(11):649-58. PubMed ID: 6655441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
